Parkinson disease: Etiology, pathogenesis and future of gene therapy

Neuroscience Research

Volumn 41, Issue 1, 2001, Pages 5-12

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Gene; Lewy body; Mutation; Parkin; Ubiquitin

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEURITE PROMOTING FACTOR; PESTICIDE; ROTENONE;

DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; HUMAN; LEWY BODY; NERVE TRANSPLANTATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; STRIATONIGRAL DEGENERATION;

EID: 0034882629     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-0102(01)00254-1     Document Type: Article

References (68)

1. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe
2. GSTM1 and mEPHX polymorphisms in Parkinson disease and age of onset
3. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding α-synuclein
4. Mesencephalic dopaminergic neurons protected by GDNF from oxotomy induced degeneration in the adult brain
5. Dopaminergic neurons intrinsic to the primate striatum
6. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
7. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson disease
8. A one-hit model of cell death in inherited neuronal degeneration
9. Long term behavioral recovery in Parkinson rats by an HSV vector expressing tyrosine hydroxylase
10. A drosophila model of Parkinson disease
11. Functional recovery in parkinsonian monkeys treated with GDNF
12. α-synuclein and the Lewy body
13. The cellular chamber of doom
14. Two novel point mutations of mitochondrial t-RNA genes in histologically confirmed Parkinson disease
15. Inhibition of neuronal nitric oxide synthase prevents MPTP induced parkinsonism in baboons
16. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals
17. Point mutations (Thr240Arg and Ala311stop)in the parkin gene
18. Complete and long term rescue of lesioned adult motoneurons by lentiviral mediated expression of glial cell-line derived neurotrophic factor in the facial nucleus
19. Association of missense and 5′-spilce-site mutations in tau with the inherited dementia FTDB-17
20. Point mutation in mitochondrial genome in Parkinson disease
21. Long term gene expression and phenotypic correction using adeno-associated viral vectors in the mammalian brain
22. Mitochondrial DNA polymorphism in substantia nigra
23. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
24. Progress in the clinical and molecular genetics of familial parkinsonism
25. Molecular cloning, gene expression and identification of a splicing variant of the mouse parkin gene
26. Exonic deletion mutations of the parkin gene among sporadic patients with parkinson's disease
27. Aggresome, inclusion bodies and protein aggregation
28. Parkinson disease: analysis of mitochondrial DNA in minozygotic twins
29. MPTP induces α-synuclein aggregation in the substantia nigra of baboons
30. Ala 30 Pro mutation in the gene encoding α synuclein in Parkinson disease
31. Epidemiology versus genetics in Parkinson disease: progress in resolving an age old debate
32. Deletion in the parkin gene and the genetic heterogeneity in a Greek family with early onset Parkinson disease
33. Ring fingers mediate ubiquitin conjugating enzyme (E2) dependent ubiquitination
34. Association between early-onset Parkinson disease and mutations in the parkin gene
35. Treatment of early Parkinson disease
36. Membrane association and protein conformation of α-synuclein in intact neuron
37. Immunocytochemical characterization of catacholaminergic neurons in the rat striatum following dopamine depleting lesions
38. Deficiencies in complex I subunit of the respiratory chain in Parkinson disease
39. Combating Parkinson disease-step three
40. Origin of the mutation in the parkin gene in Europe: exon rearrangements are independent recurrent events whereas point mutations may result from founder effects
41. A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia
42. Mutations in the α-synuclein gene identified in families with Parkinson disease
43. Tau is a candidate gene for chromosome 17 frontotemporal dementia
44. New dopaminergic neurons in Parkinson disease striatum
45. Transgenic mice with increased Cu/Zn superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
46. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
47. A 5 year study of the incidence of dyskinesia in patients with early Parkinson disease who were treated with ropinirole and levodopa
48. Association of coffee and caffeine intake with the risk of Parkinson disease
49. Evidence for mitochondrial dysfunction in Parkinson disease: a critical appraisal
50. Rapid degradation of a large fraction of newly synthesized proteins by proteosomes
51. Molecular etiology of Parkinson disease: recent progress
52. Familial Parkinson disease gene product parkin is a ubiquitin-protein ligase
53. Mitochondrial oxidative phosphorylation defects in Parkinson disease
54. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
55. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson disease family
56. Dopamine agonists in early therapy for Parkin disease
57. Parkinson disease in twins
58. Aggregates in neurodegenerative disease: crowds and power
59. Prevalence of homozygous deletions of the parkin gene in a cohort of patients with sporadic and familial Parkinson's disease
60. Polymorphism in the parkin gene in sporadic Parkinson disease
61. Doubts over cell therapy for Parkinson disease
62. Progression of parkinsonism and loss of cognitive function in Alzheimer disease
63. Mutation analysis and association study of the UCHL1 gene in German Parkinson disease patients
64. Parkin functions as an E2 dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein CDCrel-1
65. The engagement of Sec 61P in the ER dislocation process